Search Results - "de Bruijn, Peter"

Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases by IJzerman, Nikki S., Filipe, Wills F., Bruijn, Peter de, Buisman, Florian E., Doorn, Leni van, Doornebosch, Pascal G., Holster, Jessica J., Grootscholten, Cecile, Grünhagen, Dirk J., van Bommel, Christian P.E., Homs, Marjolein Y.V., Kok, Niels F.M., Verhoef, Cornelis, Koerkamp, Bas Groot, Kuhlmann, Koert F.D., Mathijssen, Ron H.J., Koolen, Stijn L.W.

“…Floxuridine’s high hepatic extraction ratio and short elimination half-life allows maximum liver exposure with minimal systemic side-effects. This study…”
Get full text

Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment by Buck, Stefan A. J., Braal, C. Louwrens, Hofman, Maaike M., Oomen-de Hoop, Esther, Bruijn, Peter de, Ghobadi Moghaddam-Helmantel, Inge M., Hussaarts, Koen G. A. M., Vastbinder, Mijntje B., van Rossum-Schornagel, Quirine C., van Schaik, Ron H. N., Jager, Agnes, Koolen, Stijn L. W., Mathijssen, Ron H. J.

“…Introduction: In breast cancer patients treated with the anti-estrogen tamoxifen, low concentrations of the active metabolite endoxifen are associated with…”
Get full text

Integration of experimental facilities: A joint effort for establishing a common knowledge base in experimental work on hydrogen safety by Reinecke, Ernst-Arndt, Huebert, Thomas, Tkatschenko, Isabelle, Kessler, Armin, Kuznetsov, Mike, Wilkins, M., Hedley, David, Azkarate, Inaki, Proust, Christophe, Acosta-Iborra, Beatriz, Gavrikov, B., De Bruijn, Peter C.J., Marangon, Alessia, Teodorczyk, Andrzej, Grafwallner, A.

“…In the area of hydrogen safety, research facilities are essential for the experimental investigation of relevant phenomena, for testing devices and safety…”
Get full text

Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib by Veerman, G.D. Marijn, Lam, Mei H., Mathijssen, Ron H.J., Koolen, Stijn L.W., de Bruijn, Peter

“…The development and full validation of a sensitive and selective ultra-performance liquid chromatography/tandem mass spectrometry (UPLC–MS/MS) method are…”
Get full text

Effectiveness and cost-effectiveness of early assisted discharge for chronic obstructive pulmonary disease exacerbations: the design of a randomised controlled trial by Utens, Cecile M A, Goossens, Lucas M A, Smeenk, Frank W J M, van Schayck, Onno C P, van Litsenburg, Walter, Janssen, Annet, van Vliet, Monique, Seezink, Wiel, Demunck, Dirk R A J, van de Pas, Brigitte, de Bruijn, Peter J, van der Pouw, Anouschka, Retera, Jeroen M A M, de Laat-Bierings, Petra, van Eijsden, Loes, Braken, Maria, Eijsermans, Riet, Rutten-van Mölken, Maureen P M H

“…Exacerbations of chronic obstructive pulmonary disease (COPD) are the main cause for hospitalisation. These hospitalisations result in a high pressure on…”
Get full text

CYP3A422 genotype and systemic exposure affect paclitaxel-induced neurotoxicity by de Graan, Anne-Joy M, Elens, Laure, Sprowl, Jason A, Sparreboom, Alex, Friberg, Lena E, van der Holt, Bronno, de Raaf, Pleun J, de Bruijn, Peter, Engels, Frederike K, Eskens, Ferry A L M, Wiemer, Erik A C, Verweij, Jaap, Mathijssen, Ron H J, van Schaik, Ron H N

“…Paclitaxel is used for the treatment of several solid tumors and displays a high interindividual variation in exposure and toxicity. Neurotoxicity is one of…”
Get full text

The influence of green tea extract on nintedanib’s bioavailability in patients with pulmonary fibrosis by Veerman, G.D.Marijn, van der Werff, Sanne C., Koolen, Stijn L.W., Miedema, Jelle R., Oomen-de Hoop, Esther, van der Mark, Sophie C., Chandoesing, Prewesh P., de Bruijn, Peter, Wijsenbeek, Marlies S., Mathijssen, Ron H.J.

“…Nintedanib is an oral small-molecule kinase inhibitor and first-line treatment for idiopathic pulmonary fibrosis. Nintedanib is a substrate of the drug efflux…”
Get full text

Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases by Rietveld, Pascale C.S., Guchelaar, Niels A.D., van Eerden, Ruben A.G., de Boer, Nadine L., de Bruijn, Peter, Sassen, Sebastiaan D.T., Madsen, Eva V.E., Koch, Birgit C.P., Verhoef, Cornelis, Burger, Jacobus W.A., Mathijssen, Ron H.J., Koolen, Stijn L.W.

“…Peritoneal metastases (PM) commonly occur in colorectal cancer patients. Systemic chemotherapy yields poor outcomes for these patients. It is hypothesised that…”
Get full text

Influence of Drug Formulation on OATP1B-Mediated Transport of Paclitaxel by NIEUWEBOER, Annemieke J. M, SHUIYING HU, CHUNSHAN GUI, HAGENBUCH, Bruno, GHOBADI MOGHADDAM-HELMANTEL, Inge M, GIBSON, Alice A, DE BRUIJN, Peter, MATHIJSSEN, Ron H. J, SPARREBOOM, Alex

“…Taxane antineoplastic agents are extensively taken up into hepatocytes by OATP1B-type transporters before metabolism and excretion. Because the…”
Get full text

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel by de Graan, Anne-Joy M, Lancaster, Cynthia S, Obaidat, Amanda, Hagenbuch, Bruno, Elens, Laure, Friberg, Lena E, de Bruijn, Peter, Hu, Shuiying, Gibson, Alice A, Bruun, Gitte H, Corydon, Thomas J, Mikkelsen, Torben S, Walker, Aisha L, Du, Guoqing, Loos, Walter J, van Schaik, Ron H N, Baker, Sharyn D, Mathijssen, Ron H J, Sparreboom, Alex

“…Docetaxel is extensively metabolized by CYP3A4 in the liver but mechanisms by which the drug is taken up into hepatocytes remain poorly understood. We…”
Get full text

Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients by Belderbos, Bodine P S, Bins, Sander, van Leeuwen, Roelof W F, Oomen-de Hoop, Esther, van der Meer, Nelly, de Bruijn, Peter, Hamberg, Paul, Overkleeft, Esther N M, van der Deure, Wendy M, Lolkema, Martijn P, de Wit, Ronald, Mathijssen, Ron H J

“…In ongoing clinical research on metastatic castration-resistant prostate cancer (mCRPC) treatment, the potential enhanced efficacy of the combination of…”
Get full text

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study by Tullemans, Bibian M E, Brouns, Sanne L N, Swieringa, Frauke, Sabrkhany, Siamack, van den Berkmortel, Franchette W P J, Peters, Natascha A J B, de Bruijn, Peter, Koolen, Stijn L W, Heemskerk, Johan W M, Aarts, Maureen J B, Kuijpers, Marijke J E

“…Tyrosine kinase inhibitors (TKIs), such as sunitinib, are used for cancer treatment, but may also affect platelet count and function with possible hemostatic…”
Get full text

Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma by de Bruijn, Peter, Kuip, Evelien J.M., Lam, Mei-Ho, Mathijssen, Ron H.J., Koolen, Stijn L.W.

“…•Sensitive methods for the quantitation of hydromorphone, morphine, fentanyl and the metabolites norfentanyl, morphine-3ß-glucuronide and…”
Get full text

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study by ENGELS, Frederike K, LAOS, Walter J, VAN DER BOL, Jessica M, DE BRUIJN, Peter, MATHIJSSEN, Ron H. J, VERWEIJ, Jaap, MATHOT, Ron A. A

“…Docetaxel pharmacokinetic (PK) parameters, notably clearance and exposure (AUC), are characterized by large interindividual variability. The purpose of this…”
Get full text

Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer by van Eerden, Ruben A. G., van Doorn, Leni, de Man, Femke M., Heersche, Niels, Doukas, Michail, van den Bosch, Thierry P. P., Oomen-de Hoop, Esther, de Bruijn, Peter, Bins, Sander, Ibrahim, Eman, Nikkessen, Suzan, Friberg, Lena E., Koolen, Stijn L. W., Spaander, Manon C. W., Mathijssen, Ron H. J.

“…Background: Data from previous work suggests that there is no correlation between systemic (plasma) paclitaxel exposure and efficacy in patients treated for…”
Get full text

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio by Lee, Clara Inkyung, Low, Siew Kee, Maldonado, Ricardo, Fox, Peter, Balakrishnar, Bavanthi, Coulter, Sally, de Bruijn, Peter, Koolen, Stijn L.W., Gao, Bo, Lynch, Jodi, Zdenkowski, Nicholas, Hui, Rina, Liddle, Christopher, Mathijssen, Ron H.J., Wilcken, Nicholas, Wong, Mark, Gurney, Howard

“…CYP2D6 protein activity can be inferred from the ratio of N-desmethyl-tamoxifen (NDMT) to endoxifen (E). CYP2D6 polymorphisms are common and can affect CYP2D6…”
Get full text

Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen by Braal, C. Louwrens, Hussaarts, Koen G. A. M., Seuren, Lieke, Oomen‑deHoop, Esther, de Bruijn, Peter, Buck, ·Stefan A. J., Bos, Monique E. M. M., Thijs‑Visser, Martine F., Zuetenhorst, Hanneke J. M., Mathijssen‑van Stein, Daniëlle, Vastbinder, Mijntje B., van Leeuwen, Roelof W. F., van Gelder, Teun, Koolen, Stijn L. W., Jager, Agnes, Mathijssen, Ron H. J.

“…Unfortunately, the original version of the article was published with incorrect copyright as “© Springer Science + Business Media, LLC, part of Springer Nature…”
Get full text

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma by Hussaarts, Koen G A M, van Doorn, Leni, Bins, Sander, Sprengers, Dave, de Bruijn, Peter, van Leeuwen, Roelof W F, Koolen, Stijn L W, van Gelder, Teun, Mathijssen, Ron H J

“…Hepatocellular carcinoma (HCC) recurrence after liver transplantation occurs in approximately 20% of patients. Most of these patients use immunosuppressant…”
Get full text

Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer by Kuip, Evelien J M, Oldenmenger, Wendy H, Thijs-Visser, Martine F, de Bruijn, Peter, Oosten, Astrid W, Oomen-de Hoop, Esther, Koolen, Stijn L W, Van der Rijt, Carin C D, Mathijssen, Ron H J

“…The transdermal fentanyl patch is widely used to treat cancer-related pain despite its wide inter- and intrapatient variability in pharmacokinetics. The aim of…”
Get full text

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib by Hussaarts, Koen G. A. M., van Doorn, Leni, Eechoute, Karel, Damman, Jeffrey, Fu, Qiang, van Doorn, Nadia, Eisenmann, Eric D., Gibson, Alice A., Oomen-de Hoop, Esther, de Bruijn, Peter, Baker, Sharyn D., Koolen, Stijn L. W., van Gelder, Teun, van Leeuwen, Roelof W. F., Mathijssen, Ron H. J., Sparreboom, Alex, Bins, Sander

“…Prior studies have demonstrated an organic anion transporter 6 (OAT6)-mediated accumulation of sorafenib in keratinocytes. The OAT6 inhibitor probenecid…”
Get full text